Base de dados : MEDLINE
Pesquisa : D27.505.696.277.950 [Categoria DeCS]
Referências encontradas : 7716 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 772 ir para página                         

  1 / 7716 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29308601
[Au] Autor:Ostinelli EG; Jajawi S; Spyridi S; Sayal K; Jayaram MB
[Ad] Endereço:Department of Health Sciences, Università degli Studi di Milano, Via Antonio di Rudinì 8, Milan, Italy, 20142.
[Ti] Título:Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).
[So] Source:Cochrane Database Syst Rev;1:CD008074, 2018 01 08.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. OBJECTIVES: To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggression or agitation (rapid tranquillisation). SEARCH METHODS: On 11 December 2014 and 11 April 2017, we searched the Cochrane Schizophrenia Group's Study-based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. SELECTION CRITERIA: All randomised controlled trials (RCTs) that randomised people with psychosis-induced aggression or agitation to receive either intramuscular aripiprazole or another intramuscular intervention. DATA COLLECTION AND ANALYSIS: We independently inspected citations and, where possible, abstracts, ordered papers and re-inspected and quality assessed these. We included studies that met our selection criteria. At least two review authors independently extracted data from the included studies. We chose a fixed-effect model. We analysed dichotomous data using risk ratio (RR) and the 95% confidence intervals (CI). We analysed continuous data using mean differences (MD) and their CIs. We assessed risk of bias for included studies and used GRADE to create 'Summary of findings' tables. MAIN RESULTS: Searching found 63 records referring to 21 possible trials. We could only include three studies, all completed over the last decade, with 885 participants, of which 707 were included for quantitative analyses in this systematic review. Due to limited comparisons, small size of trials and a paucity of investigated and reported 'pragmatic' outcomes, evidence was mostly graded as low or very low quality. No trials reported useful data for one of our primary outcomes of tranquil or asleep by 30 minutes. Economic outcomes were also not reported in the trials.When compared with placebo, fewer people in the aripiprazole group needed additional injections compared to the placebo group (2 RCTs, n = 382, RR 0.69, 95% CI 0.56 to 0.85, very low-quality evidence). Clinically important improvement in agitation at two hours favoured the aripiprazole group (2 RCTs, n = 382, RR 1.50, 95% CI 1.17 to 1.92, very low-quality evidence). The numbers of non-responders after the first injection also favoured aripiprazole (1 RCT, n = 263, RR 0.49, 95% CI 0.34 to 0.71, low-quality evidence). Although no effect was found, more people in the aripiprazole compared to the placebo group experienced adverse effects (1 RCT, n = 117, RR 1.51, 95% CI 0.93 to 2.46, very low-quality evidence).Aripiprazole required more injections compared to haloperidol (2 RCTs, n = 477, RR 1.28, 95% CI 1.00 to 1.63, very low-quality evidence), with no significant difference in agitation (2 RCTs, n = 477, RR 0.94, 95% CI 0.80 to 1.11, very low-quality evidence), and similar non-responders after first injection (1 RCT, n = 360, RR 1.18, 95% CI 0.78 to 1.79, low-quality evidence). Aripiprazole and haloperidol did not differ when taking into account the overall number of people that experienced at least one adverse effect (1 RCT, n = 113, RR 0.91, 95% CI 0.61 to 1.35, very low-quality evidence).Compared to aripiprazole, olanzapine was better at reducing agitation (1 RCT, n = 80, RR 0.77, 95% CI 0.60 to 0.99, low-quality evidence) and had a more favourable effect on global state change scores (1 RCT, n = 80, MD 0.58, 95% CI 0.01 to 1.15, low-quality evidence), both at two hours. No differences were found in terms of experiencing at least one adverse effect during the 24 hours after treatment (1 RCT, n = 80, RR 0.75, 95% CI 0.45 to 1.24, very low-quality evidence). However, participants allocated to aripiprazole experienced less somnolence (1 RCT, n = 80, RR 0.25, 95% CI 0.08 to 0.82, low-quality evidence). AUTHORS' CONCLUSIONS: The available evidence is of poor quality but there is some evidence aripiprazole is effective compared to placebo and haloperidol, but not when compared to olanzapine. However, considering that evidence comes from only three studies, caution is required in generalising these results to real-world practice. This review firmly highlights the need for more high-quality trials on intramuscular aripiprazole in the management of people with acute aggression or agitation.
[Mh] Termos MeSH primário: Agressão/efeitos dos fármacos
Antipsicóticos/administração & dosagem
Aripiprazol/administração & dosagem
Agitação Psicomotora/tratamento farmacológico
[Mh] Termos MeSH secundário: Agressão/psicologia
Antipsicóticos/efeitos adversos
Aripiprazol/efeitos adversos
Benzodiazepinas/administração & dosagem
Haloperidol/administração & dosagem
Seres Humanos
Injeções Intramusculares
Agitação Psicomotora/psicologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Tranquilizantes/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Tranquilizing Agents); 12794-10-4 (Benzodiazepines); 82VFR53I78 (Aripiprazole); J6292F8L3D (Haloperidol); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD008074.pub2


  2 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28758203
[Au] Autor:Ostinelli EG; Brooke-Powney MJ; Li X; Adams CE
[Ad] Endereço:Department of Health Sciences, Università degli Studi di Milano, Via Antonio di Rudinì 8, Milan, Italy, 20142.
[Ti] Título:Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
[So] Source:Cochrane Database Syst Rev;7:CD009377, 2017 07 31.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Haloperidol used alone is recommended to help calm situations of aggression or agitation for people with psychosis. It is widely accessible and may be the only antipsychotic medication available in limited-resource areas. OBJECTIVES: To examine whether haloperidol alone is an effective treatment for psychosis-induced aggression or agitation, wherein clinicians are required to intervene to prevent harm to self and others. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (26th May 2016). This register is compiled by systematic searches of major resources (including AMED, BIOSIS CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings, with no language, date, document type, or publication status limitations for inclusion of records into the register. SELECTION CRITERIA: Randomised controlled trials (RCTs) involving people exhibiting aggression and/or agitation thought to be due to psychosis, allocated rapid use of haloperidol alone (by any route), compared with any other treatment. Outcomes of interest included tranquillisation or asleep by 30 minutes, repeated need for rapid tranquillisation within 24 hours, specific behaviours (threat or injury to others/self), adverse effects. We included trials meeting our selection criteria and providing useable data. DATA COLLECTION AND ANALYSIS: We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included studies. For binary data we calculated risk ratio (RR), for continuous data we calculated mean difference (MD), and for cognitive outcomes we derived standardised mean difference (SMD) effect sizes, all with 95% confidence intervals (CI) and using a fixed-effect model. We assessed risk of bias for the included studies and used the GRADE approach to produce 'Summary of findings' tables which included our pre-specified main outcomes of interest. MAIN RESULTS: We found nine new RCTs from the 2016 update search, giving a total of 41 included studies and 24 comparisons. Few studies were undertaken in circumstances that reflect real-world practice, and, with notable exceptions, most were small and carried considerable risk of bias. Due to the large number of comparisons, we can only present a summary of main results.Compared with placebo, more people in the haloperidol group were asleep at two hours (2 RCTs, n=220, RR 0.88, 95%CI 0.82 to 0.95, very low-quality evidence) and experienced dystonia (2 RCTs, n=207, RR 7.49, 95%CI 0.93 to 60.21, very low-quality evidence).Compared with aripiprazole, people in the haloperidol group required fewer injections than those in the aripiprazole group (2 RCTs, n=473, RR 0.78, 95%CI 0.62 to 0.99, low-quality evidence). More people in the haloperidol group experienced dystonia (2 RCTs, n=477, RR 6.63, 95%CI 1.52 to 28.86, very low-quality evidence).Four trials (n=207) compared haloperidol with lorazepam with no significant differences with regard to number of participants asleep at one hour (1 RCT, n=60, RR 1.05, 95%CI 0.76 to 1.44, very low-quality of evidence) or those requiring additional injections (1 RCT, n=66, RR 1.14, 95%CI 0.91 to 1.43, very low-quality of evidence).Haloperidol's adverse effects were not offset by addition of lorazepam (e.g. dystonia 1 RCT, n=67, RR 8.25, 95%CI 0.46 to 147.45, very low-quality of evidence).Addition of promethazine was investigated in two trials (n=376). More people in the haloperidol group were not tranquil or asleep by 20 minutes (1 RCT, n=316, RR 1.60, 95%CI 1.18 to 2.16, moderate-quality evidence). Acute dystonia was too common in the haloperidol alone group for the trial to continue beyond the interim analysis (1 RCT, n=316, RR 19.48, 95%CI 1.14 to 331.92, low-quality evidence). AUTHORS' CONCLUSIONS: Additional data from new studies does not alter previous conclusions of this review. If no other alternative exists, sole use of intramuscular haloperidol could be life-saving. Where additional drugs are available, sole use of haloperidol for extreme emergency could be considered unethical. Addition of the sedating promethazine has support from better-grade evidence from within randomised trials. Use of an alternative antipsychotic drug is only partially supported by fragmented and poor-grade evidence. Adding a benzodiazepine to haloperidol does not have strong evidence of benefit and carries risk of additional harm.After six decades of use for emergency rapid tranquillisation, this is still an area in need of good independent trials relevant to real-world practice.
[Mh] Termos MeSH primário: Agressão/efeitos dos fármacos
Haloperidol/administração & dosagem
Agitação Psicomotora/tratamento farmacológico
Transtornos Psicóticos/tratamento farmacológico
Tranquilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Agressão/psicologia
Antipsicóticos/administração & dosagem
Antipsicóticos/efeitos adversos
Distonia/induzido quimicamente
Haloperidol/efeitos adversos
Seres Humanos
Hipnóticos e Sedativos/administração & dosagem
Hipnóticos e Sedativos/efeitos adversos
Placebos/uso terapêutico
Transtornos Psicóticos/psicologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Sono
Tranquilizantes/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Hypnotics and Sedatives); 0 (Placebos); 0 (Tranquilizing Agents); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD009377.pub3


  3 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28631765
[Au] Autor:Battistoni I; Marini M; Caretta G; Vagnarelli F; Lucà F; Biscottini E; Lavorgna A; Procaccini V; Riva L; Vianello G; Aspromonte N; Iacoviello M; De Maria R; Valente S; Gulizia MM
[Ad] Endereço:S.O.D. Cardiologia-Emodinamica-UTIC, Dipartimento di Scienze Cardiovascolari, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona - Area Scompenso Cardiaco ANMCO.
[Ti] Título:[Noninvasive ventilation and sedation: evidence and practical tools for its utilization].
[Ti] Título:Ventilazione non invasiva e sedazione: evidenze a supporto e consigli pratici..
[So] Source:G Ital Cardiol (Rome);18(6):513-518, 2017 Jun.
[Is] ISSN:1827-6806
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:Noninvasive ventilation (NIV) has gained increased acceptance inside the critical area, since it has been shown to be effective in reducing or avoiding the need for oro-tracheal intubation. NIV efficacy is dependent on the selection of the appropriate patients and on their compliance to therapy. Actually, full collaboration is not easily reached especially in agitated patients.Sedation during NIV is useful to reduce the rate of treatment failure, but robust data to guide the development of best practice are limited and sometimes local customs appear to exert a strong influence on patterns of care. Different sedative drugs are ready for use but none of currently available agents fulfill the criteria for the ideal drug. Knowledge of the pharmacological and hemodynamic characteristics of every single sedative agent is crucial to choose the right drug for every clinical scenario. Close monitoring is mandatory to avoid adverse effects. The aim of this article is to review the currently available literature, to recognize the contraindications for sedation use and to provide practical guidance.
[Mh] Termos MeSH primário: Hipnóticos e Sedativos/uso terapêutico
Ventilação não Invasiva
[Mh] Termos MeSH secundário: Analgésicos/uso terapêutico
Hemodinâmica/efeitos dos fármacos
Seres Humanos
Hipnóticos e Sedativos/efeitos adversos
Hipnóticos e Sedativos/farmacologia
Entorpecentes/efeitos adversos
Entorpecentes/farmacologia
Entorpecentes/uso terapêutico
Cooperação do Paciente
Seleção de Pacientes
Agitação Psicomotora/tratamento farmacológico
Tranquilizantes/efeitos adversos
Tranquilizantes/farmacologia
Tranquilizantes/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics); 0 (Hypnotics and Sedatives); 0 (Narcotics); 0 (Tranquilizing Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1714/2700.27612


  4 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28035127
[Au] Autor:Kuzman M; Posavec M
[Ad] Endereço:Andrija Stampar Teaching Institute of Public Health, Mirogojska 16, 10000 Zagreb, Croatia, marinakuzman1@gmail.com.
[Ti] Título:Medical use, nonmedical use of prescription medication and risk behaviour among Croatian adolescents.
[So] Source:Psychiatr Danub;28 Suppl 2:223-233, 2016 12.
[Is] ISSN:0353-5053
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: At the drug scene some major shifts were observed, more and more reports highlighted the abuse of prescription medication. Despite the importance of controlled medication in treatment child and adolescent disorders, this increase may be a factor which influence misuse and nonmedical use of prescribed drugs among adolescents. SUBJECT AND METHODS: Croatian data from ESPAD survey in 2003, 2007 and 2011 were used, and variables selected from the international ESPAD questionnaire. Dependent variable was taking tranquilizers or sedatives prescribed by doctor in the past 12 months. Independent variables were nonmedical use of tranquilizers/sedatives, use of other psychoactive substances, school performance, truancy, delinquent behaviour, satisfaction with relationships with parents, friends, health, self-perception, financial situation and symptoms of depression. The respondents were 8849 students (4393 boys and 4456 girls) in three consecutive ESPAD surveys (2003, 2007 and 2011). RESULTS: In multivariate analysis for all three survey years the strongest predictor for prescription medication use was use of sedatives/tranquilizers without prescription (OR 6.14; CI 4.08-9.23; OR 8.16; CI4.65-14.32; OR 9.77; CI5.92-15.13). Frequent drinking and excessive drinking or drunkenness also predicted prescription medication use, (OR 1.85; CI1.10-3.10; OR 2.01: CI 1.20-3.39). Among other problem behaviours lower school performance (OR 2.92; CI 1.41-6.05; OR 2.56; CI 1.12-5.87), missed school days OR 1.59; OR1.01-2.51; OR1.72; CI 1.03-2.87), aggressive behaviour (OR 1.532; CI 1.01-2.28; OR1.65; CI 1.04-2.62), depressive symptoms (OR 2.19; CI 1.24-3.85) and poorer financial situation were connected with prescription medication use. CONCLUSION: Prescription use of tranquilizers/sedatives was predicted by nonmedical tranquilizers/sedatives use, alcohol abuse, symptoms of depression and variables indicating maladjusted behaviour. Although there is sufficient evidence that prescription medication abuse might went unobserved, the further analysis which could better explain its' role and impact is still needed.
[Mh] Termos MeSH primário: Bebedeira/epidemiologia
Depressão/epidemiologia
Hipnóticos e Sedativos/uso terapêutico
Fumar Maconha/epidemiologia
Uso Indevido de Medicamentos sob Prescrição/estatística & dados numéricos
Comportamento Problema
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
Tranquilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Agressão
Alcoolismo/epidemiologia
Croácia/epidemiologia
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Assunção de Riscos
Autoimagem
Licença Médica
Estudantes/estatística & dados numéricos
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 0 (Tranquilizing Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161231
[St] Status:MEDLINE


  5 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27657833
[Au] Autor:Ornaghi S; Davis JN; Gorres KL; Miller G; Paidas MJ; van den Pol AN
[Ad] Endereço:Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, 06510 New Haven, CT, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement, 333 Ceda
[Ti] Título:Mood stabilizers inhibit cytomegalovirus infection.
[So] Source:Virology;499:121-135, 2016 Dec.
[Is] ISSN:1096-0341
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cytomegalovirus (CMV) infection can generate debilitating disease in immunocompromised individuals and neonates. It is also the most common infectious cause of congenital birth defects in infected fetuses. Available anti-CMV drugs are partially effective but are limited by some toxicity, potential viral resistance, and are not recommended for fetal exposure. Valproate, valpromide, and valnoctamide have been used for many years to treat epilepsy and mood disorders. We report for the first time that, in contrast to the virus-enhancing actions of valproate, structurally related valpromide and valnoctamide evoke a substantial and specific inhibition of mouse and human CMV in vitro. In vivo, both drugs safely attenuate mouse CMV, improving survival, body weight, and developmental maturation of infected newborns. The compounds appear to act by a novel mechanism that interferes with CMV attachment to the cell. Our work provides a novel potential direction for CMV therapeutics through repositioning of agents already approved for use in psychiatric disorders.
[Mh] Termos MeSH primário: Infecções por Citomegalovirus/virologia
Citomegalovirus/efeitos dos fármacos
Citomegalovirus/fisiologia
Tranquilizantes/farmacologia
[Mh] Termos MeSH secundário: Amidas/farmacologia
Animais
Linhagem Celular
Células Cultivadas
Infecções por Citomegalovirus/tratamento farmacológico
Infecções por Citomegalovirus/mortalidade
Modelos Animais de Doenças
Feminino
Seres Humanos
Masculino
Camundongos
Muromegalovirus/efeitos dos fármacos
Muromegalovirus/fisiologia
Tranquilizantes/uso terapêutico
Ácido Valproico/análogos & derivados
Ácido Valproico/farmacologia
Carga Viral
Replicação Viral/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amides); 0 (Tranquilizing Agents); 3O25NRX9YG (valnoctamide); 614OI1Z5WI (Valproic Acid); RUA6CWU76G (dipropylacetamide)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160923
[St] Status:MEDLINE


  6 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27573673
[Au] Autor:Bergemann N; Paulus WE
[Ad] Endereço:Sächsisches Krankenhaus Rodewisch, Zentrum für Psychiatrie, Psychotherapie, Psychosomatik und Neurologie, Bahnhofstraße 1, 08228, Rodewisch, Deutschland. niels.bergemann@skhro.sms.sachsen.de.
[Ti] Título:[Psychopharmacotherapy during pregnancy : Which antipsychotics, tranquilizers and hypnotics are suitable?].
[Ti] Título:Psychopharmakotherapie in der Schwangerschaft : Welche Antipsychotika, Tranquilizer und Hypnotika sind geeignet?.
[So] Source:Nervenarzt;87(9):943-54, 2016 Sep.
[Is] ISSN:1433-0407
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:BACKGROUND: When administering psychotropic drugs during pregnancy not only the potential teratogenic effects on the child must be addressed but also the fetotoxic implications for pregnancy and/or the peripartum phase as well as possible neurocognitive developmental disorders must be considered. OBJECTIVE: Evaluation of the risks and benefits of administering psychotropic drugs during pregnancy or for women who wish to become pregnant. METHODS: The literature has been reviewed with the purpose of providing information on psychotropic drugs which can safely be administered during pregnancy. The review considers antipsychotics as well as tranquilizers and hypnotics. RESULTS: Data are available for a multitude of psychotropic drugs that allow a safe estimation on their suitability for use during pregnancy. CONCLUSION: When treating mental illnesses during pregnancy the option of administering drugs must not principally be ruled out. What is required is an individual assessment of benefits and risks. The risk of an untreated mental illness versus the benefit of a suitable treatment, which may include the use of medication and the potential harm to the infant must be evaluated. If certain rules are observed and a suitable drug is selected the risk to the newborn child and/or mother during pregnancy can be minimized. During pregnancy, therapeutic drug monitoring is indicated and increases the safety for use of drugs and preventing harm to both mother and infant.
[Mh] Termos MeSH primário: Anormalidades Induzidas por Medicamentos/prevenção & controle
Antipsicóticos/administração & dosagem
Hipnóticos e Sedativos/administração & dosagem
Transtornos Mentais/tratamento farmacológico
Complicações na Gravidez/tratamento farmacológico
Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente
Tranquilizantes/administração & dosagem
[Mh] Termos MeSH secundário: Anormalidades Induzidas por Medicamentos/etiologia
Esquema de Medicação
Monitoramento de Medicamentos/métodos
Quimioterapia Combinada/métodos
Medicina Baseada em Evidências
Feminino
Seres Humanos
Troca Materno-Fetal/efeitos dos fármacos
Gravidez
Efeitos Tardios da Exposição Pré-Natal/prevenção & controle
Psicofarmacologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Hypnotics and Sedatives); 0 (Tranquilizing Agents)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170916
[Lr] Data última revisão:
170916
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160831
[St] Status:MEDLINE
[do] DOI:10.1007/s00115-016-0192-z


  7 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27416676
[Au] Autor:Kundashev UK; Salenko YA; Morozov IS; Zurdinov AZ; Barchukov VG
[Ti] Título:[EFFECT OF MEDIATOR-TYPE DRUGS ON HUMAN PSYCHOPHYSIOLOGICAL STATUS DURING MODEL OPERATOR ACTIVITY].
[So] Source:Eksp Klin Farmakol;79(2):9-13, 2016.
[Is] ISSN:0869-2092
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:In a placebo-controlled study, changes in psychophysiological status of operators (38 healthy male volunteers aged 23-35 years) performing 4-hour model operator activity were evaluated after a single oral administration of typical representatives of the different classes of drugs (haloperidol, proroxan, yohimbine hydrochloride, propranolol, mesocarb, isoprenaline, Belladonna extract, anabasine hydrochloride, valproate sodium, and phenazepam), which are used for the treatment, rehabilitation and prophylaxis of common diseases. It was found that all the drugs modified to a greater or lesser extent some components of the model operator activity. Isoprenaline and phenazepam had the most negative effect on the psychophysiological indicators and quality of the modeled operator activity. The results should be considered before administration of such drugs to working operators.
[Mh] Termos MeSH primário: Atenção/efeitos dos fármacos
Estimulantes do Sistema Nervoso Central/farmacologia
Análise e Desempenho de Tarefas
Tranquilizantes/farmacologia
[Mh] Termos MeSH secundário: Adulto
Anabasina/farmacologia
Atenção/fisiologia
Alcaloides de Belladona/farmacologia
Benzodiazepinas/farmacologia
Dioxanos/farmacologia
Método Duplo-Cego
Haloperidol/farmacologia
Seres Humanos
Isoproterenol/farmacologia
Masculino
Propranolol/farmacologia
Psicofisiologia
Sidnonas/farmacologia
Ácido Valproico/farmacologia
Ioimbina/farmacologia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Belladonna Alkaloids); 0 (Central Nervous System Stimulants); 0 (Dioxanes); 0 (Sydnones); 0 (Tranquilizing Agents); 12794-10-4 (Benzodiazepines); 2Y49VWD90Q (Yohimbine); 3DSB43090Z (phenazepam); 614OI1Z5WI (Valproic Acid); 9Y8NXQ24VQ (Propranolol); J6292F8L3D (Haloperidol); L628TT009W (Isoproterenol); LMS11II2LO (Anabasine); T5WT3QN49G (proroxan); UMT8MP2NDU (sidnocarb)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160715
[Lr] Data última revisão:
160715
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160716
[St] Status:MEDLINE


  8 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27153300
[Au] Autor:Stollings JL; Bloom SL; Huggins EL; Grayson SL; Jackson JC; Sevin CM
[Ti] Título:Medication Management to Ameliorate Post-Intensive Care Syndrome.
[So] Source:AACN Adv Crit Care;27(2):133-40, 2016 Apr-Jun.
[Is] ISSN:1559-7776
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Cuidados Críticos/psicologia
Estado Terminal/psicologia
Estresse Psicológico/tratamento farmacológico
Sobreviventes/psicologia
Tranquilizantes/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Educação Continuada
Feminino
Seres Humanos
Unidades de Terapia Intensiva
Masculino
Meia-Idade
Alta do Paciente
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tranquilizing Agents)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170328
[Lr] Data última revisão:
170328
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:160507
[St] Status:MEDLINE
[do] DOI:10.4037/aacnacc2016931


  9 / 7716 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27042718
[Au] Autor:Chutko LS; Surushkina SY; Anisimova TI
[Ad] Endereço:Bechtereva Institute of Human Brain, Russian Academy of Sciences, St. Petersburg.
[Ti] Título:[Anxiety and fear in children and adolescents].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;116(1):99-103, 2016.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article presents an overview of scientific publication devoted to the study of epidemiology, etiology, pathogenesis, clinical manifestation and basic approaches to treatment of anxious-phobic disorders in children.
[Mh] Termos MeSH primário: Medo
Transtornos Fóbicos
[Mh] Termos MeSH secundário: Adolescente
Criança
Feminino
Seres Humanos
Masculino
Transtornos Fóbicos/diagnóstico
Transtornos Fóbicos/tratamento farmacológico
Transtornos Fóbicos/epidemiologia
Transtornos Fóbicos/etiologia
Tranquilizantes/uso terapêutico
Ácido gama-Aminobutírico/análogos & derivados
Ácido gama-Aminobutírico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Tranquilizing Agents); 56-12-2 (gamma-Aminobutyric Acid); T2M58D6LA8 (4-amino-3-phenylbutyric acid)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160405
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20161161199-103


  10 / 7716 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26946128
[Au] Autor:Bonini SA; Mastinu A; Maccarinelli G; Mitola S; Premoli M; La Rosa LR; Ferrari-Toninelli G; Grilli M; Memo M
[Ad] Endereço:Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
[Ti] Título:Cortical Structure Alterations and Social Behavior Impairment in p50-Deficient Mice.
[So] Source:Cereb Cortex;26(6):2832-49, 2016 06.
[Is] ISSN:1460-2199
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Alterations in genes that regulate neurodevelopment can lead to cortical malformations, resulting in malfunction during postnatal life. The NF-κB pathway has a key role during neurodevelopment by regulating the maintenance of the neural progenitor cell pool and inhibiting neuronal differentiation. In this study, we evaluated whether mice lacking the NF-κB p50 subunit (KO) present alterations in cortical structure and associated behavioral impairment. We found that, compared with wild type (WT), KO mice at postnatal day 2 present an increase in radial glial cells, an increase in Reelin protein expression levels, in addition to an increase of specific layer thickness. Moreover, adult KO mice display abnormal columnar organization in the somatosensory cortex, a specific decrease in somatostatin- and parvalbumin-expressing interneurons, altered neurite orientation, and a decrease in Synapsin I protein levels. Concerning behavior, KO mice, in addition to an increase in locomotor and exploratory activity, display impairment in social behaviors, with a reduction in social interaction. Finally, we found that risperidone treatment decreased hyperactivity of KO mice, but had no effect on defective social interaction. Altogether, these data add complexity to a growing body of data, suggesting a link between dysregulation of the NF-κB pathway and neurodevelopmental disorders pathogenesis.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Encéfalo/patologia
Subunidade p50 de NF-kappa B/metabolismo
Comportamento Social
[Mh] Termos MeSH secundário: Animais
Encéfalo/crescimento & desenvolvimento
Moléculas de Adesão Celular Neuronais/metabolismo
Células Ependimogliais/metabolismo
Células Ependimogliais/patologia
Comportamento Exploratório/efeitos dos fármacos
Comportamento Exploratório/fisiologia
Proteínas da Matriz Extracelular/metabolismo
Interneurônios/metabolismo
Interneurônios/patologia
Masculino
Camundongos Knockout
Atividade Motora/efeitos dos fármacos
Atividade Motora/fisiologia
Subunidade p50 de NF-kappa B/genética
Proteínas do Tecido Nervoso/metabolismo
Neuritos/metabolismo
Neuritos/patologia
Parvalbuminas/metabolismo
Risperidona/farmacologia
Serina Endopeptidases/metabolismo
Somatostatina/metabolismo
Sinapsinas/metabolismo
Tranquilizantes/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cell Adhesion Molecules, Neuronal); 0 (Extracellular Matrix Proteins); 0 (NF-kappa B p50 Subunit); 0 (Nerve Tissue Proteins); 0 (Parvalbumins); 0 (Synapsins); 0 (Tranquilizing Agents); 51110-01-1 (Somatostatin); EC 3.4.21.- (Serine Endopeptidases); EC 3.4.21.- (reelin protein); L6UH7ZF8HC (Risperidone)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160307
[St] Status:MEDLINE
[do] DOI:10.1093/cercor/bhw037



página 1 de 772 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde